filovirus
includ
marburgand
ebolavirus
caus
multipl
outbreak
among
human
decad
antibodi
filoviru
surfac
glycoprotein
gp
shown
provid
lifesav
therapi
nonhuman
primat
antibodi
gener
virusspecif
mani
monoclon
antibodi
mab
describ
ebola
viru
contrast
rel
describ
marburg
viru
present
ten
mab
elicit
immun
mice
use
recombin
mucindelet
gp
differ
marburg
viru
marv
strain
surprisingli
two
mab
rais
marv
gp
also
crossreact
mucindelet
gp
core
test
ebolavirus
ebola
sudan
bundibugyo
reston
epitop
mask
differ
mucinlik
domain
efficaci
mab
panel
found
recogn
novel
wing
featur
subunit
uniqu
marburg
exist
ebola
two
antiw
antibodi
confer
protect
respect
one
hour
postexposur
mice
challeng
marv
filovirus
filament
envelop
virus
caus
highli
lethal
hemorrhag
fever
human
nonhuman
primat
filoviru
famili
includ
major
genera
ebolaviru
marburgviru
newli
discov
cuevaviru
ebolaviru
genu
five
known
speci
ebola
viru
ebov
sudan
viru
sudv
bundibugyo
viru
bdbv
reston
viru
restv
forest
viru
tafv
marburgviru
genu
one
speci
eponym
name
marburg
viru
marv
marv
subdivid
differ
strain
includ
musok
ravn
angola
ravn
diverg
strain
marv
differ
genom
sequenc
marburg
strain
sometim
referenc
separ
filoviru
speci
marburg
viru
first
filoviru
identifi
sicken
laboratori
worker
handl
infect
anim
origin
uganda
marburg
viru
sinc
reemerg
least
time
import
unit
state
europ
travel
becam
infect
africa
angola
lethal
strain
marburg
viru
emerg
caus
largest
marv
outbreak
known
date
extrem
high
case
fatal
rate
emerg
ebola
viru
west
africa
caus
outbreak
unpreced
magnitud
grim
remind
devast
caus
filovirus
filovirus
present
singl
viral
protein
envelop
surfac
glycoprotein
gp
respons
attach
entri
virus
target
cell
gp
express
precursor
cleav
furin
produc
cell
yield
two
subunit
remain
link
disulfid
bond
contain
put
receptorbind
region
well
two
heavili
glycosyl
domain
glycan
cap
sit
immedi
atop
put
receptorbind
site
larger
larg
unstructur
mucinlik
domain
mucinlik
domain
contain
dens
cluster
nand
olink
glycan
like
mask
gp
immun
surveil
second
subunit
gp
term
possess
transmembran
domain
anchor
gp
viral
surfac
hydrophob
fusion
peptid
requir
fusion
ebolavirus
furin
cleavag
site
lie
residu
entir
mucinlik
domain
attach
subunit
marburg
viru
howev
furin
cleavag
site
lie
residu
split
mucinlik
domain
portion
remain
attach
subunit
term
aminoacid
ntermin
extens
wing
cell
entri
macropinocytosi
filoviru
gp
undergo
addit
cleavag
host
cathepsin
proteas
endosom
cleavag
event
remov
glycan
cap
mucinlik
domain
result
loss
molecular
mass
gp
endosom
cleavag
render
gp
compet
receptor
bind
allow
expos
head
bind
share
filoviru
receptor
niemannpick
although
antibodi
broadli
crossreact
among
ebolaand
marburgviru
gp
would
highli
desir
one
antibodi
describ
recent
work
nonhuman
primat
demonstr
passiv
administr
monoclon
antibodi
mab
cocktail
gp
provid
highli
effect
postexposur
therapi
ebov
infect
polyclon
sera
marburg
viru
shown
similar
efficaci
suggest
antibodi
could
also
viabl
treatment
option
marv
infect
howev
fewer
monoclon
antibodi
cocktail
could
develop
current
avail
marv
one
human
survivor
panel
recent
describ
mab
compet
site
core
antibodi
target
epitop
marburg
gp
would
desir
order
form
treatment
cocktail
gener
monoclon
antibodi
cocktail
effect
compon
antibodi
display
synergist
effect
combin
mab
nonoverlap
epitop
significantli
increas
overal
potenc
cocktail
individu
mab
alon
mitig
antigen
escap
viru
antivir
antibodi
often
select
base
neutral
abil
mab
prevent
viral
entri
target
cell
vitro
howev
filovirus
well
virus
neutral
vitro
necessarili
correl
protect
vivo
nonneutr
antibodi
known
confer
protect
antibodydepend
cellular
cytotox
adcc
phagocytosi
prevent
viru
bud
mechan
inde
one
success
antiebov
oligoclon
cocktail
compos
entir
antibodi
potent
neutral
studi
produc
divers
panel
antibodi
marburg
viru
immun
mice
differ
strain
surfac
gp
antigen
immunogen
includ
ectodomain
marburg
strain
musok
angola
ravn
mucindelet
immunogen
use
direct
immun
respons
away
highli
variabl
mucinlik
domain
ten
antibodi
chosen
analyz
vitro
neutral
vivo
efficaci
biochem
recognit
marv
ebov
gp
antibodi
multipl
epitop
found
four
antibodi
target
novel
marvspecif
wing
epitop
confer
protect
mice
challeng
marv
separ
marvspecif
antibodi
direct
epitop
confer
protect
anoth
mab
direct
confer
protect
found
broadli
crossreact
among
core
filoviru
gp
includ
marburgand
ebolavirus
gener
marv
gpspecif
mab
balbc
mice
immun
antigen
either
marv
strain
musok
angola
ravn
fig
mice
subset
immun
boost
antigen
except
seri
eight
ten
mab
panel
mous
remain
two
mab
fig
character
bind
mab
perform
enzymelink
immunosorb
assay
elisa
recombin
gp
four
marv
strain
determin
valu
bind
differ
form
marv
ravn
gp
gp
gpcl
fig
ten
mab
exhibit
medium
bind
color
dark
yellow
high
bind
color
orang
ravn
gp
fig
seven
mab
crossreact
gp
marv
strain
fig
mab
bind
proteasecleav
ravn
gp
core
term
gpcl
well
except
antibodi
exhibit
decreas
bind
gpcl
compar
fig
addit
evalu
whether
mab
capac
bind
cellsurfac
gp
elisa
perform
viruslik
particl
vlp
bear
fulllength
wildtyp
marv
ravn
gp
eight
mab
bind
well
nearli
well
vlp
purifi
recombin
ravn
gp
contrast
exhibit
nearli
weaker
bind
vlp
gp
ectodomain
bind
vlp
lost
highest
concentr
test
fig
determin
antibodi
epitop
perform
western
blot
ravn
gp
pepscan
analysi
overlap
pin
peptid
ravn
musok
gp
five
mab
bind
five
bind
western
blot
fig
panel
pepscan
identifi
linear
epitop
four
mab
overlap
within
residu
fig
share
region
lie
extens
specif
marv
result
furin
cleavag
site
shift
ebov
marv
term
wing
fig
order
confirm
pepscan
result
engin
addit
delet
residu
term
fig
inde
bind
lost
four
antiw
mab
whilst
remain
six
mab
differ
epitop
bind
fig
definit
epitop
inform
could
identifi
pepscan
remain
antibodi
suggest
mab
bind
conform
epitop
sequenc
align
marv
gp
residu
reveal
musok
angola
complet
conserv
region
ravn
uniqu
residu
notabl
chang
residu
glu
e
ravn
ly
k
strain
fig
wing
mab
specif
marv
ravn
correspondingli
elisa
data
compar
bind
wildtyp
ravn
ravn
confirm
presenc
ly
posit
exist
strain
marv
like
hinder
bind
howev
still
retain
bind
unaffect
mutat
retain
bind
fig
result
agre
pepscan
result
base
peptid
overlap
amino
acid
defin
epitop
slightli
shift
away
posit
toward
nterminu
fig
shift
may
explain
crossreact
antiw
mab
fig
antibodi
screen
vitro
neutral
use
vsvpseudoviru
contain
marv
ravn
gp
surfac
six
ten
mab
exhibit
partial
neutral
highest
concentr
test
reduc
entri
remain
four
mab
neutral
fig
notabl
five
mab
produc
studi
exhibit
neutral
one
mab
inhibit
entri
ravn
gp
pseudovirion
polyclon
sera
mice
yield
seri
mab
reduc
entri
suggest
mab
repres
maximum
potenc
polyclon
popul
fig
human
survivor
mab
use
posit
control
reduc
pseudovirion
entri
almost
mab
evalu
vivo
protect
use
balbc
mice
challeng
lethal
dose
marv
viru
one
hour
challeng
pfu
mouseadapt
marv
ravn
mice
treat
ip
purifi
mab
two
separ
studi
perform
half
mab
repeat
studi
control
anim
studi
treat
pb
exhibit
surviv
fig
control
group
studi
treat
pb
antiha
mab
exhibit
surviv
fig
marv
mab
treatment
group
vari
wide
efficaci
rang
protect
four
mab
wing
found
moder
highli
protect
mab
confer
surviv
mab
surviv
mab
surviv
mab
surviv
monoclon
antibodi
confer
surviv
fig
mab
core
exhibit
surviv
offer
strongli
signific
protect
p
valu
mab
epitop
wing
mab
exhibit
zero
protect
fig
studi
mice
treatment
group
display
elev
diseas
score
day
fig
signific
differ
weight
loss
treatment
group
control
group
studi
mice
fair
modestli
better
group
reach
diseas
score
maximum
fulli
recov
day
fig
two
highli
crossreact
marv
antibodi
mab
also
exhibit
bind
ebola
sudan
bundibugyo
reston
viru
mucindelet
gp
elisa
fig
bind
curv
show
affin
mucincontain
ebov
gp
weak
affin
stronger
bind
ebov
gpcl
receptorbind
compet
core
strongest
equal
marv
gpcl
fig
henc
epitop
conserv
across
filoviru
famili
expos
version
marburg
viru
gp
mask
ebolaviru
gp
mucinlik
domain
glycan
cap
singl
particl
electron
microscopi
protect
antibodi
perform
complex
purifi
antigen
neg
stain
class
averag
fab
complex
marv
ravn
show
one
two
three
fab
bound
dens
trimer
gp
core
fig
contrast
class
averag
wing
mab
complex
marv
ravn
show
singl
fab
bound
gp
distanc
away
high
densiti
gp
trimer
fig
deuterium
exchang
mass
spectrometri
dxm
studi
suggest
gp
wing
region
unstructur
like
flexibl
fig
ensur
wing
epitop
artifici
posit
compar
biolog
relev
mucincontain
gp
also
perform
em
fab
complex
complet
ectodomain
marv
ravn
gp
imag
obtain
similar
one
fab
bind
per
trimer
fig
like
footprint
fab
drawn
onto
marv
ravn
gpcl
crystal
structur
fig
studi
small
panel
mab
target
marv
gp
isol
immun
mice
confer
greatest
vivo
protect
direct
novel
wing
domain
marv
wing
region
marvspecif
portion
mucinlik
domain
attach
epitop
exist
ebolavirus
entir
mucinlik
domain
attach
although
studi
size
small
note
wingdirect
mab
obtain
mice
immun
mucindelet
ravn
gp
may
tempt
assum
epitop
mask
mucinlik
domain
howev
antiw
mab
abl
access
epitop
mucincontain
gp
neutral
pseuodvirus
bear
mucincontain
gp
provid
vivo
efficaci
challeng
marburg
viru
believ
elicit
antiw
antibodi
use
ravn
may
instead
result
greater
homogen
stabil
ravn
marv
antigen
sevenyear
protein
engin
effort
laboratori
identifi
crystalliz
version
marv
gp
inde
found
gp
produc
strain
ravn
homogen
lesser
tendenc
aggreg
strain
marv
homogen
may
lead
improv
present
protect
epitop
within
studi
interest
note
among
panel
murin
mab
recent
publish
panel
human
survivor
mab
antibodi
bind
base
marv
gp
identifi
base
gp
common
site
neutral
ebolavirus
epitop
target
antiebov
neutral
antibodi
well
antisudv
mab
perhap
presenc
flexibl
marv
block
access
site
gp
core
nonetheless
antibodi
direct
gp
wing
potenti
fulli
protect
repres
novel
epitop
marv
therapeut
cocktail
design
protect
mab
promis
bind
high
affin
gp
ravn
henc
protect
marv
strain
may
limit
contrast
monoclon
antibodi
confer
efficaci
yet
crossreact
mucincontain
gp
four
strain
marv
howev
murin
isotyp
typic
exhibit
weaker
immun
effector
activ
murin
replac
constant
domain
framework
may
improv
vivo
efficaci
panel
two
mab
identifi
also
bind
gp
core
ebolavirus
antibodi
bind
marv
gp
bind
ebola
sudan
bundibugyo
reston
gp
mucinlik
domain
delet
fig
henc
highli
conserv
epitop
expos
marburgviru
gp
mask
ebolaviru
gp
observ
parallel
obtain
panel
antimarv
gp
antibodi
isol
human
survivor
support
structur
observ
orient
mucinlik
domain
differ
ebov
marv
inde
crossfiloviru
antigp
antibodi
reactiv
ebola
marburg
yet
elicit
ebolaviru
gp
immunogen
antibodi
yet
isol
ebolaviru
survivor
although
filoviru
crossreact
mab
confer
surviv
anoth
antibodi
like
may
use
immunotherapeut
cocktail
highli
conserv
epitop
would
like
less
subject
antigen
escap
antibodi
also
direct
pattern
bind
distinct
mab
panel
lower
affin
gpcl
gp
suggest
epitop
partial
lost
upon
cleavag
could
similar
glycan
cap
binder
like
ebov
gp
unfortun
due
singl
prefer
orient
fab
particl
neg
stain
em
grid
highresolut
reconstruct
could
determin
better
understand
epitop
await
studi
afford
protect
vivo
highli
crossreact
among
marv
ectodomain
gp
ebola
viru
vitro
neutral
necessarili
effect
predictor
vivo
protect
one
antiebov
cocktail
compos
entir
nonneutr
weakli
neutral
mab
yet
still
confer
vivo
protect
presum
recruit
immun
effector
function
recent
cocktail
formul
includ
mix
neutral
nonneutr
antibodi
studi
mab
marv
none
mab
offer
signific
vitro
neutral
yet
sever
confer
partial
complet
vivo
protect
marv
one
hour
challeng
although
studi
limit
scope
note
among
set
antibodi
exhibit
vitro
neutral
also
confer
best
vivo
protect
one
mab
weakli
neutral
offer
protect
mab
futur
studi
perform
longer
time
period
challeng
lower
treatment
dose
test
limit
efficaci
individu
mab
promis
mab
could
evalu
nonhuman
primat
nhp
predict
therapeut
potenti
human
work
provid
biochem
structur
map
antibodi
epitop
marv
gp
analyz
conserv
epitop
among
differ
strain
marv
find
antibodi
novel
wing
epitop
confer
protect
vivo
two
mab
differ
site
confer
protect
mab
cocktail
thought
effect
compon
antibodi
display
synergist
effect
combin
mab
nonoverlap
epitop
significantli
increas
overal
potenc
cocktail
individu
mab
alon
mitig
antigen
escap
viru
panel
antibodi
describ
although
limit
number
provid
three
possibl
compon
antimarv
immunotherapeut
cocktail
core
mab
neutral
mr
mab
mab
wing
mab
futur
studi
determin
limit
protect
therapeut
potenti
antibodi
deliv
combin
studi
approv
carri
accord
protocol
provid
institut
anim
care
use
committe
iacuc
tsri
emerg
biosolut
niaid
usamriid
research
usamriid
conduct
complianc
anim
welfar
act
feder
statut
regul
relat
anim
adher
principl
state
guid
care
use
laboratori
anim
nation
research
council
marburg
angola
ravn
tsri
marburg
viru
gp
immunogen
use
rais
antibodi
emerg
design
produc
tsri
dna
encod
marv
ectodomain
residu
mucin
delet
residu
clone
deriv
invitrogen
pdisplay
vector
deriv
vector
pgdfr
sequenc
replac
ctermin
purif
tag
either
ha
strep
tag
largescal
product
perform
pei
transfect
polysci
inc
mw
plasmid
confluent
gnticel
atcc
corn
cellstack
supernat
harvest
four
day
posttransfect
concentr
centram
tangenti
flow
system
affin
purifi
use
streptactin
qiagen
antiha
roch
affin
resin
trimer
isol
size
exclus
chromatographi
sec
mm
tri
mm
nacl
ph
tb
order
improv
furin
cleavag
process
express
decreas
aggreg
improv
yield
purifi
trimer
bulki
hydrophob
residu
near
furin
cleavag
site
mutat
construct
ravn
mutat
includ
angola
mutat
includ
marburg
musok
angola
ibt
marburg
viru
antigen
use
rais
antibodi
ibt
produc
ibt
musok
produc
pei
transfect
cell
deriv
pdisplay
plasmid
contain
ctermin
hatag
protein
purifi
antiha
affin
roch
follow
lectin
affin
superos
size
exclus
chromatographi
ge
healthcar
angola
produc
baculoviru
infect
bactobac
invitrogen
cell
invitrogen
accord
manufactur
protocol
purifi
via
ctermin
tag
sepharos
resin
ge
healthcar
product
six
weekold
balbc
mice
inject
subcutan
sc
volum
pb
purifi
marv
gp
freund
complet
adjuv
cfa
brenntag
biosector
addit
boost
inject
intraperiton
ip
day
gp
incomplet
freund
adjuv
ifa
brenntag
biosector
thereaft
mice
receiv
final
push
purifi
gp
pb
ip
conduct
fusion
standard
protocol
use
produc
hybridoma
cell
line
monoclon
antibodi
specif
antigen
purifi
protein
g
resin
mice
immun
ravn
rais
antibodi
mice
immun
ravn
boost
two
time
complex
ravn
bound
fab
rais
antibodi
mice
immun
angola
yield
antibodi
immun
mice
emerg
perform
accord
anim
use
protocol
aup
approv
protocol
manag
review
committe
pmrc
univers
manitoba
product
six
weekold
balbc
mice
immun
intramuscularli
im
three
time
purifi
marv
gp
glucopyranosyl
lipid
adjuv
gla
adjuv
week
interv
boost
intraven
iv
antigen
day
harvest
spleenlymph
node
fusion
standard
protocol
use
produc
hybridoma
cell
line
monoclon
antibodi
specif
antigen
purifi
protein
g
resin
mice
immun
musok
yield
antibodi
mice
immun
angola
yield
antibodi
immun
mice
ibt
perform
accord
aup
approv
nobl
life
scienc
iacuc
product
immun
mice
perform
bioquant
inc
san
diego
ca
six
weekold
balbc
mice
inject
subcutan
sc
purifi
cfa
follow
addit
boost
week
interv
antigen
ifa
ip
ifa
sc
conduct
fusion
standard
protocol
use
produc
hybridoma
cell
line
mab
purifi
protein
g
resin
purifi
filoviru
gp
antigen
prepar
filoviru
ectodomain
elisa
western
blot
em
dxm
produc
tsri
drosophila
cell
except
musok
gp
produc
ibt
cell
describ
musok
briefli
effecten
reagent
qiagen
use
transfect
cell
pmtpuro
plasmid
contain
streptag
filoviru
gp
gene
interest
follow
stabl
select
transfect
cell
puromycin
insect
xpress
protein
free
medium
lonza
secret
gp
ectodomain
express
induc
supernat
harvest
day
protein
affin
purifi
use
streptactin
resin
qiagen
follow
purif
via
superdex
sec
tb
cleav
core
ectodomain
marv
marv
gpcl
produc
incub
ravn
mg
trypsin
sigma
hour
tb
ph
follow
sec
purif
cleav
core
ectodomain
ebov
ebov
gpcl
produc
incub
ebov
thermolysin
sigma
overnight
room
temperatur
rt
tb
buffer
plu
cacl
follow
sec
purif
sdspage
gel
compar
puriti
molecular
weight
sever
antigen
shown
panel
b
vlp
prepar
viruslik
particl
produc
cotransfect
cell
pcagg
plasmid
express
fulllength
marv
ravn
gp
marv
supernat
harvest
sixti
hour
vlp
pellet
xg
minut
wash
pb
repellet
vlp
pellet
gentli
resuspend
pb
contain
triton
dilut
pb
use
coat
antigen
elisa
western
blot
purifi
marv
ravn
gp
reduc
nonreduc
sampl
run
sdspage
gel
transfer
onto
pvdf
immobilon
membran
millipor
membran
block
overnight
milk
biorad
blot
grade
tween
pbst
incub
room
rt
antimarv
mab
concentr
milk
pbst
wash
pbst
incub
goat
antimous
antihuman
alkalin
phosphatas
ap
conjug
antibodi
dilut
ap
activ
detect
sigmafast
bcipnbt
substrat
recognit
variou
form
gp
crossreact
elisa
determin
half
maxim
effect
concentr
mab
test
bind
gp
gpcl
marv
ravn
concentr
rang
use
serial
dilut
data
analyz
use
graphpad
prism
softwar
determin
crossreact
mab
test
bind
marv
angola
musok
ebov
gp
mucincontain
musok
gp
readili
aggreg
bind
fig
report
high
medium
low
rather
quantit
valu
antibodi
analyz
bind
antigen
ebov
sudv
bdbv
restv
well
ebov
gpcl
bind
curv
determin
concentr
rang
use
serial
dilut
elisa
perform
follow
corn
highbind
microtit
plate
coat
filoviru
gp
antigen
block
bsa
pb
hour
rt
incub
antimarv
mab
bsa
hour
rt
plate
incub
goat
antimous
igg
hl
hrp
conjug
secondari
thermo
scientif
bsa
hour
rt
plate
wash
step
pb
contain
tween
color
develop
produc
tmb
substrat
thermo
scientif
stop
sulfur
acid
quantifi
measur
absorb
pepscan
wing
analysi
attempt
map
linear
epitop
mab
test
elisa
pepscan
synthet
peptid
design
ravn
gp
sequenc
overlap
amino
acid
pepscan
repeat
mab
peptid
design
musok
gp
sequenc
control
wing
pepscan
defin
epitop
addit
elisa
perform
marv
gp
lack
mld
wing
term
wingdirect
antibodi
evalu
bind
wildtyp
ravn
ravn
contain
point
mutant
coat
antigen
point
mutant
elisa
produc
cell
repres
mammalian
glycoprofil
around
wing
pseudoviru
neutral
assay
vesicular
stomat
viru
vsv
pseudovirion
contain
gfp
gene
place
vsv
envelop
glycoprotein
gene
bear
fulllength
glycoprotein
marv
ravn
gener
previous
describ
pseudovirion
incub
antivsv
g
mab
gift
takada
hour
rt
incub
antimarv
gp
mab
fb
gibco
addit
hour
rt
pseudovirionmab
complex
ad
vero
cell
atcc
monolay
plate
multipl
infect
moi
hour
infect
evalu
count
gfpexpress
cell
experi
perform
triplic
standard
deviat
display
mammalian
cell
line
use
studi
test
neg
mycoplasma
contamin
tsri
anim
work
procedur
infecti
marburg
virus
perform
biosafeti
level
facil
usamriid
male
femal
balbc
mice
week
age
challeng
intraperiton
ip
plaqueform
unit
mouseadapt
marv
ravn
two
separ
studi
one
hour
postexposur
mice
treat
ip
purifi
monoclon
antimarv
gp
antibodi
pb
mgml
pb
alon
studi
two
includ
addit
neg
control
group
treat
antiha
igg
pb
test
group
consist
anim
total
mice
antibodi
blind
ibt
submiss
usamriid
research
anim
weigh
monitor
daili
day
period
postchalleng
point
mice
euthan
accord
iacucapprov
protocol
anim
symptomat
examin
twice
per
day
health
score
use
follow
paramet
normal
reduc
groomingruffl
fur
subdu
lethargichunch
postur
provid
dietgel
hydrat
unrespons
euthan
health
score
treatment
group
fig
shown
one
two
anim
surviv
respect
anim
exclud
analysi
experi
random
balbc
mice
use
experi
obtain
frederick
cancer
research
develop
center
nation
cancer
institut
frederick
md
statist
analysi
graphpad
prism
softwar
use
calcul
p
valu
use
logrank
mantel
cox
test
treatment
group
compar
correspond
pb
control
either
studi
p
valu
consid
nonsignific
ns
purifi
ravn
gpcl
evalu
deuterium
exchang
mass
spectrometri
dxm
previous
describ
neg
stain
em
analysi
marv
ravn
ectodomain
produc
drosophila
cell
describ
fab
fragment
gener
standard
papain
digest
sigma
igg
purifi
mono
q
ge
healthcar
ionexchang
chromatographi
five
molar
excess
fab
ad
trimer
gp
allow
bind
overnight
complex
dilut
tb
buffer
deposit
onto
carbonco
copper
mesh
grid
plasma
clean
sec
gatan
stain
sec
uranyl
format
stain
blot
edg
grid
allow
dri
data
automat
collect
leginon
use
fei
tecnai
electron
microscop
oper
kev
electron
dose
e
magnif
result
pixel
size
specimen
plane
collect
spirit
x
ccd
camera
specimen
plane
collect
tietz
x
ccd
camera
imag
acquir
constant
defocu
valu
variou
tilt
angl
particl
pick
automat
use
dog
picker
place
particl
stack
use
appion
softwar
referencefre
class
averag
calcul
use
particl
bin
xmipp
cluster
align
softwar
sort
particl
per
class
support
inform
fig
western
blot
antigp
marv
mab
incub
reduc
dtt
nonreduc
dtt
purifi
ravn
gp
b
nonreduc
sdspage
gel
sever
purifi
marv
gp
ebola
antigen
cell
note
ravn
gpcl
run
larger
ebola
gpcl
due
extra
mass
wing
